Education
About Us
Working with TipRanks
Follow Us
Piramal Pharma Limited (IN:PPLPHARMA)
:PPLPHARMA
Total Valuation
Piramal Pharma Limited has a market cap or net worth of ₹259.27B. The enterprise value is ₹135.88B.
Market Cap₹259.27B
Enterprise Value₹135.88B
Share Statistics
Piramal Pharma Limited has 1,329,248,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,329,248,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Piramal Pharma Limited’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 5.90%.
Return on Equity (ROE)0.01
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)5.90%
Return on Capital Employed (ROCE)0.30
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.58
Inventory Turnover1.40
Valuation Ratios
The current PE Ratio of Piramal Pharma Limited is 331.66. Piramal Pharma Limited’s PEG ratio is 0.00.
PE Ratio331.66
PS Ratio0.00
PB Ratio5.51
Price to Fair Value3.72
Price to FCF-965.41
Price to Operating Cash Flow650.37
PEG Ratio0.00
Income Statement
In the last 12 months, Piramal Pharma Limited had revenue of 91.51B and earned 911.30M in profits. Earnings per share was 0.69.
Revenue91.51B
Gross Profit59.20B
Operating Income36.12B
Pretax Income4.15B
Net Income911.30M
EBITDA14.04B
Earnings Per Share (EPS)0.69
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Piramal Pharma Limited pays an annual dividend of ₹0.109, resulting in a dividend yield of 0.06%
Dividend Per Share₹0.109
Dividend Yield0.06%
Payout Ratio19.46%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.55
52-Week Price Change21.80%
50-Day Moving Average208.33
200-Day Moving Average226.87
Relative Strength Index (RSI)46.42
Average Volume (3m)241.38K
Important Dates
Piramal Pharma Limited upcoming earnings date is Jul 31, 2025, During Market Hours (Confirmed).
Last Earnings DateMay 14, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend DateJul 16, 2025
Financial Position
Piramal Pharma Limited as a current ratio of 1.54, with Debt / Equity ratio of 4.25%
Current Ratio1.54
Quick Ratio0.93
Debt to Market Cap0.16
Net Debt to EBITDA3.10
Interest Coverage Ratio8.57
Taxes
In the past 12 months, Piramal Pharma Limited has paid 3.24B in taxes.
Income Tax3.24B
Effective Tax Rate0.78
Enterprise Valuation
Piramal Pharma Limited EV to EBITDA ratio is 24.63, with an EV/FCF ratio of 151.72.
EV to Sales3.78
EV to EBITDA24.63
EV to Free Cash Flow151.72
EV to Operating Cash Flow38.75
Balance Sheet
Piramal Pharma Limited has ₹5.21B in cash and marketable securities with ₹48.56B in debt, giving a net cash position of ₹43.35B billion.
Cash & Marketable Securities₹5.21B
Total Debt₹48.56B
Net Cash₹43.35B
Net Cash Per Share₹32.62
Tangible Book Value Per Share₹30.14
Margins
Gross margin is 56.50%, with operating margin of 39.47%, and net profit margin of 1.00%.
Gross Margin56.50%
Operating Margin39.47%
Pretax Margin4.53%
Net Profit Margin1.00%
EBITDA Margin15.34%
EBIT Margin6.87%
Analyst Forecast
The average price target for Piramal Pharma Limited is ₹287.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target₹287.50
Price Target Upside33.78% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―